- Home
- HUHU vs ALVR Comparison
HUHU vs ALVR Comparison
Compare HUHU & ALVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUHU
- ALVR
- Stock Information
- Founded
- HUHU 2015
- ALVR 2013
- Country
- HUHU China
- ALVR United States
- Employees
- HUHU N/A
- ALVR N/A
- Industry
- HUHU
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HUHU
- ALVR Health Care
- Exchange
- HUHU NYSE
- ALVR Nasdaq
- Market Cap
- HUHU N/A
- ALVR 52.2M
- IPO Year
- HUHU 2024
- ALVR 2020
- Fundamental
- Price
- HUHU $4.70
- ALVR $0.45
- Analyst Decision
- HUHU
- ALVR Sell
- Analyst Count
- HUHU 0
- ALVR 1
- Target Price
- HUHU N/A
- ALVR $0.50
- AVG Volume (30 Days)
- HUHU 152.2K
- ALVR 325.1K
- Earning Date
- HUHU 02-22-2025
- ALVR 11-12-2024
- Dividend Yield
- HUHU N/A
- ALVR N/A
- EPS Growth
- HUHU 13.14
- ALVR N/A
- EPS
- HUHU 0.08
- ALVR N/A
- Revenue
- HUHU $17,492,735.00
- ALVR N/A
- Revenue This Year
- HUHU N/A
- ALVR N/A
- Revenue Next Year
- HUHU N/A
- ALVR N/A
- P/E Ratio
- HUHU $57.60
- ALVR N/A
- Revenue Growth
- HUHU 33.03
- ALVR N/A
- 52 Week Low
- HUHU $3.52
- ALVR $0.40
- 52 Week High
- HUHU $9.89
- ALVR $1.05
- Technical
- Relative Strength Index (RSI)
- HUHU N/A
- ALVR 41.21
- Support Level
- HUHU N/A
- ALVR $0.42
- Resistance Level
- HUHU N/A
- ALVR $0.48
- Average True Range (ATR)
- HUHU 0.00
- ALVR 0.04
- MACD
- HUHU 0.00
- ALVR 0.01
- Stochastic Oscillator
- HUHU 0.00
- ALVR 48.98
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.